Patent · US Active

Soluble CD33 for treating myelodysplastic syndromes (MDS)

US11584787B2 · kind B2 · utility

0Cited by

2References

16Claims

0Family size

Assignee

H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. · US

Inventors

Alan F. List · Tampa, US
Sheng Wei · Tampa, US

Key dates

Filing date	Jun 25, 2019
Grant date	Feb 21, 2023
Priority date	—
Expiry date	May 4, 2040

Classification

Technology area (CPC G)Physics
CPC primaryG01N2500/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are compositions and methods for treating disease or condition caused or exacerbated by S100A9 activity, such as myelodysplastic syndromes (MDS) using a composition comprising an effective amount of a CD33/S100A9 inhibitor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.